Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q4 FY26ended Jun 30, 2026 | Aug 6, 2026 | $2.64 | +2.3% | $1.46B | +8.6% | $2.89 |
| Q3 FY26ended Mar 31, 2026 | Apr 30, 2026 | $2.74 | +10.5% | $1.43B | +10.8% | $2.79 |
| Q2 FY26ended Dec 31, 2025 | — | $2.68 | +14.5% | $1.42B | +11.0% | — |
| Q1 FY26ended Sep 30, 2025 | — | $2.37 | +12.3% | $1.34B | +9.1% | — |
| Q4 FY25ended Jun 30, 2025 | — | $2.58 | +30.3% | $1.35B | +10.2% | — |
| Q3 FY25ended Mar 31, 2025 | — | $2.48 | +21.6% | $1.29B | +7.9% | — |
| Q2 FY25ended Dec 31, 2024 | — | $2.34 | +64.8% | $1.28B | +10.3% | — |
| Q1 FY25ended Sep 30, 2024 | — | $2.11 | +41.6% | $1.22B | +11.1% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe ResMed shares, not any token. As of Aug 6, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q4 FY24ended Jun 30, 2024 | — | $1.98 | — | $1.22B | — | — |
| Q3 FY24ended Mar 31, 2024 | — | $2.04 | — | $1.20B | — | — |
| Q2 FY24ended Dec 31, 2023 | — | $1.42 | — | $1.16B | — | — |
| Q1 FY24ended Sep 30, 2023 | — | $1.49 | — | $1.10B | — | — |